# OnCo record paper-brahmer-anti-pd-l1-phase-1-nejm-2012 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-brahmer-anti-pd-l1-phase-1-nejm-2012/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-brahmer-anti-pd-l1-phase-1-nejm-2012" ;
  schema:name "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer"@en ;
  schema:description "The first PD-L1 antibody trial treated 207 people across several cancers; melanoma, kidney and lung cancers responded, and none of the 14 pancreatic cancer patients did."@en ;
  schema:url <https://onco.cc/key-papers/paper-brahmer-anti-pd-l1-phase-1-nejm-2012/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1200694>, <https://pubmed.ncbi.nlm.nih.gov/22658128/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1200694> ;
  schema:datePublished "2012"^^xsd:gYear ;
  schema:author "Brahmer JR, Tykodi SS, Chow LQ, et al." ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/cold-vs-hot/> ;
  onco:journals <https://onco.cc/journals/nejm/> .